Background:
AKI is common in ECMO patients, with a variety of proposed mechanisms. We sought to describe the impact of laboratory evidence of ECMO-associated intravascular hemolysis on AKI and renal replacement therapy (RRT).
Methods:
This retrospective cohort study included patients treated with ECMO at a single center over ten years. The primary outcome was a composite of time to RRT or AKI (by creatinine based KDIGO criteria) after ECMO start. Serum creatinine closest to ECMO start time was considered the pre-ECMO baseline and used to determine abnormal kidney function at ECMO start. The patient’s subsequent creatinine values were used to identify AKI on ECMO. Multivariable cause-specific cox proportional hazards models were used to assess the impact of separate markers of intravascular hemolysis on the time to the composite outcome after controlling for confounders.
Results:
501 children were evaluated with a median age 1.2 years, 56% male. Four separate multivariable models, each with a different marker of hemolysis (plasma free hemoglobin, LDH, minimum platelet count, minimum daily hemoglobin) were used to examine the impact on the composite outcome of AKI/RRT. An elevated plasma free hemoglobin, the most specific of these hemolysis markers, demonstrated an almost three-fold higher adjusted hazard for the composite outcome (HR 2.9, p-value <0.01, 95% CI 1.4-5.6). Elevated LDH was associated with an adjusted hazard ratio of 3.1 (p-value <0.01, 95% CI 1.7-5.5). Effect estimates were also pronounced in a composite outcome of only more severe AKI, stage 2+ AKI/RRT: HR 6.6 (p-value <0.01, 95% CI 3.3-13.2) for plasma free hemoglobin and 2.8 (p-value <0.01, 95% CI 1.5-5.6) for LDH.
Conclusions:
Laboratory findings consistent with intravascular hemolysis on ECMO were independently associated with a higher hazard of a composite outcome of AKI/RRT in children undergoing ECMO.